Digimarc Recognized as Technology Leader
Digimarc Recognized as Technology Leader
Today Digimarc Corporation (NASDAQ: DMRC), inventor of the Digimarc Discover? platform featuring the imperceptible Digimarc Barcode, announced the company has been recognized for driving innovative solutions into the retail sector. Digimarc is named by ABI Research as a Smart Retail Hot Tech Innovator for 2017. The company was also recognized in IEEE Spectrum for its intellectual property, ranking third for its patent portfolio in the computer software category behind only Microsoft and VMWare, and ahead of software powerhouses including Adobe, Citrix, Oracle, SAP and Symantec.
“Our vision is to enrich everyday living through our patented technologies and applications such as Digimarc Barcode,” said Bruce Davis, chief executive officer, Digimarc. “We have a long tradition of technology innovation and a computing platform that enables future application development and growth by our customers and partners. It’s gratifying to see this recognition of our industry-leading innovation.”
ABI Research identified solutions and innovative companies that are enabling a retail revolution. According to the firm, the selection criteria for “retail hot tech innovators” identified the companies that are the fastest growing in the retail technology industry based on the number of implementations internationally, and the amount of funds raised from capital investors that will continue to fuel their growth.
In “Patent Power 2017,” IEEE Spectrum reports on intellectual property from leading companies. Its Pipeline Power rating ranks patent portfolios by number of U.S. patents granted in the most recent full year (2016) and quality, as measured by statistical assessment of important qualities such as growth, impact, originality and general applicability.
Additional information about Digimarc Barcode can be viewed here.
About Digimarc
Digimarc Corporation (NASDAQ: DMRC) is a pioneer in the automatic identification of everyday objects such as product packaging and virtually any media, including print, images and audio. Based on the patented Intuitive Computing Platform (ICPT), Digimarc provides innovative and comprehensive automatic recognition technologies to simplify search, and transform information discovery through unparalleled reliability, efficiency and security. Digimarc has a global patent portfolio, which includes over 1,100 granted and pending patents. These innovations include state-of-the-art identification technology, Digimarc Barcode, as well as Digimarc Discover? software for barcode scanning and more. Digimarc is based in Beaverton, Oregon, with technologies deployed by major retailers and consumer brands, central banks, U.S. states, film companies and professional sports franchises, among others. Visit digimarc.com and follow us @digimarc to learn more about The Barcode of EverythingT.
SOURCE Digimarc Corporation
Cutting Supplements for Women
This article will detail a lot of the methods and products used by women bodybuilders to achieve great fitness results while being health safe.
So many questions …. What are the best steroids for women to use and what are the potential benefits and side effects? Almost every female bodybuilder has questions about steroids women can use. Steroids have become somewhat accepted for use by men, at least socially. But there are still many questions about the efficacy.
Like men, women are interested in taking steroids too. There are many reasons for this, but the most common is to get a slim and muscular look, and get rid of fat. Women are more concerned about their physique, that’s why more and more women are used chemical bodybuilders for building a great body.
Legal Anavar is a safe, natural, extremely effective legal alternative to the prescription steroid Oxandrolone, also known as Anavar and goes by many other street names. This legal anabolic is manufactured with the exact same goals in mind as its pharmaceutical counterpart, but without the dangerous side.
A woman’s metabolism is different than a man’s. The fact is, women retain more fat than men. There are different supplements available for women, a popular product is one made by CrazyBulk. Detailed view : legal steroids safe for women
There are many women who are genetically gifted, but those women are few and far between. Most women do not have perfect genetics and struggle when trying to lose weight, burn fat, and firm up their muscles. In order to get a ripped and shredded most women will not tell you that besides diet and exercise, they use a variety of performance enhancement drugs (steroids).
Anabolic steroids are commonly used by fitness models, yes the ugly truth is, women tend to carry around more body fat than men, in order for women to stimulate their metabolism and burn fat there are 3 steroids women will take to help burn fat and maintain a lean body.
Most women are not going to compete in a fitness or bodybuilding competition, however, many want to have a great looking body, taking steroids does have side effects, however, there are safe steroid alternatives that can offer similar benefits. Legal steroids offer the same benefits by mimicking the effects of anabolic steroids.
Unfortunately, most bodybuilding supplements target male athletes and bodybuilders, what most companies do not realize is that there are just as many women that look for supplements to help improve their physique and performance. Unlike men, women have a harder time eliminating body fat. That is why some supplement companies have turned their focus to female bodybuilders and fitness models.
We all carry weight in different places and the last place where that weight seems to come off is the stomach or abdominal area, however it is not practical to think that we can completely eat our way to shredded abs, sure you can eat clean healthy foods but that is not the complete secret to shredded abs. What we can do is watch what we eat and eliminate foods that provoke our body to store fat.
The body needs protein and lean protein acts as a thermogenic that can help burn fat, it has been proven time and time again that high protein diets are more effective than low calorie or low fat diets, this means eating plenty of fish, chicken, lean beef and green leafy vegetables.
The goal of a cutting cycle is to maintain as much muscle as you can while eliminating body fat. Everyone has muscle, however, the only way to show it off is by getting rid of the fat that is covering up the muscle.
What is Methodology X
Methodology X is a cutting edge 28 day home workout that is specially tailored for women. The Book is written by Dan Roberts who has been training famous supermodels and A -list actresses for the last two decades. The Book comes in an electronic format (E-Book) that can easily be downloaded to any Apple or Android device including any computer (laptop) tablet or smartphone. Read more on the topic : fitness model competition training
What is BlackWolf Hunt?
BlackWolf Hunt for women is a premium workout supplement for women to get you through the toughest training sessions. Inta-Workout means you take it while you train. It will keep you strong and help you maintain energy levels no matter how hard the workout is. BlackWolf Hunt helps carry you through the rest of the way so you can train strong with plenty of energy. Read more on the topic : Best pre workout supplements
Steroids can be a fast way to achieve a jaw-dropping physique but sometimes it really isn’t worth the risk. For health reasons, it’s probably a good idea to stay away from them and that’s why supplements are so popular, they are not that strong but they do give the athlete and edge.
Caida.eu reports huge increase in traffic
Caida.eu is an established general web directory launched in 2013.
It receives 20,000 websites submissions per month and due the quality of approved listings and increased popularity it reached around 10,000 unique visitors per month on average for 2017.
Because of the long list of pending review submissions the approval time is very long, around 6 month.
You can submit your website here : http://www.caida.eu
Cryolife tech news
Asian’s Godfather of Cord Blood, Professor Takahashi Tsuneo Joined the “Cryolife Cord Blood Bank” and “Hong Kong Medisun”
In May 2017, CRYOLIFE Cord Blood Bank (Hong Kong Medisun Medical Group members) formally appointed the Godfather of Cord Blood in Asia, Japanese regenerative medicine expert Professor Takahashi Tsuneo as the Chief Scientist. Professor Takahashi will lead all the cord blood stem cell research projects. Professor Takahashi has eras of experience in the field of regenerative medicine. In the past few decades, Professor Takahashi has established the standards of the Cryo-Cord Blood in Asia and lead a new prospective in the application and development of the cord blood industry.
It is well believes that by the joining of Professor Takahashi will convey a new development stage in the field of cord blood stem cells in Hong Kong. It will bring new opportunities for the expansion of Medisun Medical Group and the Cryolife Cord Blood Bank.
Professor Takahashi Tsuneo is committed to the field of regenerative medicine for more than 40 years (mainly in the field of stem cells and cord blood bank). Currently he serves as Chief Executive Officer of Japan LIFEBANK and Chief Scientist of Hong Kong Cryolife Cord Blood Bank (Cryolife is a members of the Medisun Group). Prof. Takashi Tsuneo graduated from the Hokkaido University in Sapporo, Japan with a Ph.D. degree. He became the scientist in the Red Cross of Bethesda, Maryland. He later worked at the Research center for Arthritis, Diabetes and Kidney diseases of the National Institutes of Health in Bethesda, Maryland. Professor Takahashi Tsuneo returned to Japan, became the Red Cross Hokkaido Blood Center’s Research Director in Sapporo. Professor Takahashi is not only a founding member of the International Cord Blood Bank Alliance (NETCORD), but also Director of the Tokyo Cord Blood Bank Cell Treatment Center at the University of Tokyo, Japan, and Director of Cellular Research and Development for research center for cell therapy in New York. Professor Takahashi is a Visiting Professor at a number of well-known institutions, including: Department of Cellular Processing, Institute of Medical Sciences, University of Tokyo, Head of Hematology, Tokyo University Hospital, Head of Embryonic Stem Cell Research, Faculty of Forensic Medicine, Kyoto University, Kobe University Institute of Medicine and Pathology, and Department of Medicine, Peking University, China.
Application of Cord Blood
Cord blood is originated in the fetus, and collected at the umbilical cord ligation when separated from the residual placenta. Nearly a decade of research and discovered that umbilical cord blood contain the human hematopoietic and the hematopoietic stem cells of the immune system. It can be used for hematopoietic stem cell transplantation, for the treatment of more than 80 kinds of diseases. Thus, the cord blood has become an important source of hematopoietic stem cells, especially for no directly related family members. The hematopoietic stem cells is a very important human biological for treatment of diseases.
Worldwide, cord blood has been used to treat various types of Leukemia, Aplastic Anemia, Lymphoma, Multiple Myeloma, Neuroblastoma, Mucopolysaccharide disease, Thalassemia, Bone Marrow Dysplasia syndrome, Primary Immunodeficiency Disease, Chronic Granuloma and other 80 kinds of diseases.
Clinical application case
* The world’s first cord blood transplantation: In 1988, a 5-year-old French boy, suffering from Cooley’s Anemia has been treated with the cord blood transplantation and with completely recovered.
* The world’s first autologous cord blood transplantation: In 1997, a 14-month-old Brazilian girl, with autologous cord blood successfully cured Neuroblastoma.
* The world’s first double dosages of cord blood transplantation: In 2000, the Institute of Hematology of the Peking University used the world’s first double dose of cord blood transplantation for the treatment of Acute Lymphoblastic Leukemia with good result. Now, the patient weight of 95 kg, is having a healthy life.
* Asia’s first autologous cord blood transplantation: In 2009, Beijing Children’s Hospital, a pediatric patient using his own cord blood for the treatment of Neuroblastoma. This is the first case of autologous cord blood treatment for pediatric case. The baby is treated and being fine after the transplantation.
* China treated a youngest and light weight baby: In 2009, Shanghai Dao Pei Hospital has successfully treated a 2 months old baby only weight – 5 kg, by using the cord blood transplantation treatment for Primary Immunodeficiency Disease.
* In China, the first mother received the son’s cord blood transplantation as treatment: In 2009, Chongqing Xinqiao Hospital, a female patient suffering from an Acute Non-Lymphocytic Leukemia was treated by using her son’s umbilical cord blood, together with his husband’s bone marrow for transplantation. She was discharged from the Intensive Care Unit after one month from the transplantation. This is the first case of mother using her child’s cord blood for transplantation.
Treatment prospects
Cell therapy has been a biological way for the treatment of a number of diseases in the 21st century. At the end of May 2014, the worldwide of related clinical research on the cord blood cell therapy, registered with the United States National Institutes of Health (NIH) reached a total of 928.
CRYOLIFE Cord Blood Bank – Hong Kong’s first private cord blood bank
CRYOLIFE Cord Blood Bank is the only one in Hong Kong with the most international professional certification, and is highly recommended by gynecologist, physicians and parents. CRYOLIFE was established in 1996 to create the first private cord blood storage program in Asia. Prior to the establishment of the cord blood bank in Japan, Singapore, mainland China, Taiwan and Malaysia. Cryolife upgrades the standards in the development and research in the laboratory equipment. It is the leader in Hong Kong and Asian in the cord blood industry. CRYOLIFE has been recognized by the American Association of Blood Banks (AABB) since 2007 as one of the world’s first recognized AABB-approved cord blood banks, and range the first 50 in the Cord Blood Bank’s list. Continuous assessment were done in 2009, 2011, 2013 and 2015 and has successfully passed the review, and gain the AABB certification until the end of 2017. The company is the only one in Hong Kong which has obtained a 10 consecutive years’ certification in the private cord blood bank. (In February 2017) Hong Kong Medisun Medical Group acquired 51% stake in CRYOLIFE Cord Blood Bank as its controlling shareholder.)
MEDISUN MEDICAL GROUP
Headquartered in Hong Kong, Headquartered in Hong Kong, the company is committed to investing in R & D and commercialization of global regenerative medicine products, as well as professional medical investment groups in top hospitals and treatment centers.
Medisun invests extensively in regenerative medicine and stem cell patented technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, neurological diseases, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical and the US Mayo Clinic, Harvard University Stem Cell Research Institute, Johns Hopkins School of Life Science Center launched a long-term cooperation program, co-investment in regenerative medicine and stem cell therapy technology. Medisun collaborates with them as the business owned holdings and holds global intellectual property rights.
The Medisun Regenerative Medical Center is located in Kowloon, Hong Kong , with 50,000 square feet of stem cell GMP production base, cancer treatment center and anti-aging center, bringing together European, Japanese, American and individual Chinese experts for rigorous professional development process by providing immune cell therapy and a variety of stem cell treatments. Medisun is also the Asian Center, a representative of the Mayo Clinic Asia service agencies. It provides Mayo remote consultation, the second diagnosis and treatment, so that Chinese patients can not enjoy the authority of the medical services. Mayo Clinic provides more than three thousand biomedical tests for the most predictable health protection for our customers’ health.
Medisun Regenerative Medicine Center (Mayo Asia Medical Service Center | Cancer Treatment Center | Anti-Aging Center)
Medisun Medical Laboratory (Hong Kong)
Source : http://www.medisun.hk/
Medisun and Tsinghua University starting collaboration
The founding of Enterprise Fund for the Tsinghua University and Medisun Cell Technological Research and Regenerative Medicine
In April 26, 2017 Medisun Medical Group and Tsinghua University held a signing ceremony, formally announced the establishment of the “Tsinghua Medisun Cell Technology Research Institute” and setting up the “Tsinghua Medisun Cell Technology and Regenerative Enterprise Investment Fund”. At the time of the 106th anniversary of Tsinghua University, the signing ceremony was presided by the prof. Dong Chen, Dean of the School of medicine, Tsinghua University, with the signing officials, the Chairman of Medisun Medical Group Mr. Danny Wong, The Executive Director of Medisun Medical Group Dr. Wen Feng, Vice President of Tsinghua University and the Chairman of Tsinghua University Education Foundation Yang Bin, Tsinghua University Education Foundation Secretary-General Li Jiaqiang, Medical School’s party secretary Hongbo and many other college leaders attended the signing ceremony.
The signing parties: Tsinghua University School of Medicine Dong Chen and Medisun Medical Group Chairman Danny Wong
The global leading platform of Regenerative Medicine on Cell Technology : The Enterprise Fund for the Cell Technological Research and Regenerative Medicine is based on the advance technology, professional staffing, skill proficiency, resources and management experience of the Medisun Medical Group. Further enhanced by the quality and scientific research platform offered by the Tsinghua University, for the collaboration with the School of Medicine and the Tsinghua Chang Gung Memorial Hospital and other affiliated institutions. To focus on cell technology and cell therapy in the area of education, training, scientific research, clinical transformation and industrial development. Through the combination of the above strong elements, to reinforce the professional leadership of the School of Medicine of Tsinghua University.
The two parties will actively cooperate with the integration of professionals and the high-quality resources, to build the institute as:
* The world’s leading cell technology platform to support the training of professionals
* The world’s leading cell technology platform for research, development and clinical transformation
* The world’s leading platform for international cooperation for development of cell technology
* China as the most influential authority on cell technology and related laws, regulations and operational standards
Cell Technology and Regenerative Medicine Enterprise Investment Fund
At the time of setting up the research institute, Tsinghua University and Medisun Medical Group, National Investment Funds Limited (The Directors of Medisun Medical Group) also co-sponsored the establishment of Tsinghua Medisun Cell Technology and Regenerative Enterprise Investment Fund. The movement will attract more financial ventures to participate and invest the technology for further research, development and clinical transformation. The increase of the social capital can increase the investment in scientific research, and reduce the burden on the government and university’s expenses. This is to ensure the scientific research is carried out normally, to achieve the scientific research objectives. Secondly, the investment from the enterprise can motivate the research staff for better efficiency of the scientific research and to enhance the productivity. Thereby to enhance the brand value and social benefits.
The Enterprise Investment Fund will be included in the Tsinghua University School of Medicine’s overall industrial strategy. According to the management standard of the School of medicine, it will be used for the research and development, and clinical transformation with the Tsinghua Chang Gung Memorial Hospital, to accomplish the combination of leap forward development strategy. At the same time, to set up a 10 years plan on the Enterprise Investment Fund. The profit from the operating outcome will donate to the Institute for teaching, research and related charity projects to promote the cell technology and regenerative medicine for an sustainable development.
Life Science – a main agenda on the 13th Five – year Plan
Life science is one of the most rapid developing area of the twentieth century and become one of the most striking discipline of natural life science. From the early stage of the development of the cell technology and cell therapy has already heading a medical revolution. In compare with the traditional drug therapy and surgery, the cell technology has develop a new means as the third choice of treatment. With advance improvement, it can has a broad market and potential for further expansion. The General Secretary Xi Jinping pointed out at the National Science and Technology Innovation Conference that stem cell research, early diagnosis of cancer markers, human genome sequencing and other basic scientific breakthroughs, all these can become an influential factors for China to face the world. Enterprises place an important force for integration of science, technology and economic growth. As the investment on research, development and transformation will become the main drive of the technological innovation. To adjust the existing industry and local research institutions, enrich enterprise R & D strength, support enterprises to build national technology and innovation center, cultivate the industry which could become the business pioneer. The collaboration between Medisun and Tsinghua University is a strong response to the National thirteen five years plan’s development direction, and to create a comprehensive platform for research and development.
The cooperation with the Medisun and Tsinghua University will lead the growth of cell technology and cell therapy in China. This will further promote the establishment of a comprehensive laws and regulation on cellular technology, industry standards, norms, system for cultivation and high-end and quality scientific research. Also training of medical personnel, support the international exchanges, enhance the ability of independent innovation by building a world class cell technology and cell therapy transformation platform. Then China will own the world high-end standard expertise and transformation cell technology enterprise. See more details on http://www.medisun.hk/.
PT. Kamadjaja Logistics
PT. Kamadjaja Logistics was recently named Frost & Sullivan’s 2017 Indonesia Domestic Warehouse Services Provider of the Year at the annual Frost & Sullivan Indonesia Excellence Awards ceremony, held at the Mandarin Oriental Hotel, Jakarta on 28 November 2017.
“Recognizing the importance of innovation and meeting customer needs, PT. Kamadjaja Logistics has focused on developing and improving its warehousing infrastructure and technologies. The company’s cutting edge warehousing facilities such as its successful KLOG PARK establishments have enabled customers to derive maximum value from top-notch services, allowing the company to enjoy a better relationship with customers,” said Norazah Bachok, Research Analyst for Transportation & Logistics at Frost & Sullivan.
She continued, “PT. Kamadjaja Logistics also aims for more partnerships with various regional participants to boost opportunities. An extensive product portfolio, new business chain ventures, regional partnerships, and expansion strategies allow the company to enhance its brand recognition and value in the industry.”
“We are delighted to receive the 2017 Indonesia Domestic Warehouse Services Provider of the Year award from Frost & Sullivan. This recognition is a huge encouragement to the team as we strive to provide value to our customers by delivering innovative and excellent logistics services,” said Ivy Kamadjaja, Deputy CEO of PT. Kamadjaja Logistics.
The recipients of the annual Frost & Sullivan Indonesia Excellence Awards were identified based on in-depth research conducted by Frost & Sullivan’s analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends.
The short-listed companies were then evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.
About PT. Kamadjaja Logistics
PT. Kamadjaja Logistics is widely recognized as a pioneer in the logistics industry in Indonesia. Established five decades ago it is now the largest Indonesian company that provides integrated and modern logistics solutions. Equipped with 29 Distribution Centers spread over 16 major cities in Indonesia and covering over 355 destinations, PT. Kamadjaja Logistics has the largest nationwide logistics network in the country.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion
Contact:
Fuad Misbah
Corporate Communications – Indonesia
Email: fuad.misbah@frost.com
http://www.frost.com
SEO Services by SEOmarketplace.net
SeoMarketplace.net offers all types of SEO services and products:
1. White Hat SEO Services
2. Content Writing
3. Internet Marketing
4. Website Design
5. Link and Online Exposure Building
6. Social Media Exposure promotions
The guidelines we use are :
1. Quality Services
2. Affordable Prices
3. Low Profit margins to improve the client retention
You can read about our SEO service here : http://www.seomarketplace.net/
The Mary C. O’Keefe Cultural Center Will Host Hurricane Harvey Benefit Show September 24th
Who knew a devastating hurricane in the Texas Gulf Coast would inspire so many communities across America to pitch-in and help? But that’s exactly what’s happening September 24th in Ocean Springs, Mississippi when “FRANK & LIZA” come to the Mary C. This strong community already knows the impact of a record-breaking storm. In 2005, Hurricane Katrina ravaged their own coastline. But today, it’s Houston and the Texas coast that urgently need the help.
Thanks to the Mary C. O’Keefe Cultural Center, the exhilarating musical tribute to “Frank Sinatra & Liza Minnelli” will come to Ocean Springs for one Sunday matinee benefiting the Hurricane Harvey Relief Fund. The show is a rapid-paced musical journey through the classic and timeless hits of Frank Sinatra and the Broadway-like song and dance spectacle that is Liza Minnelli’s trademark.
Described as “warm, witty and sexy”, the Las Vegas show features a delightful exchange of music, humor and dazzling duets between two of the most talented artists working today – Dave Halston and Suzanne Goulet. Together, “FRANK & LIZA” will not only thrill a willing audience, they will make it easy for virtually anyone to assist in the Hurricane Harvey relief effort.
Seating is limited. Tickets are available online now for $25.
About the Hurricane Harvey Relief Fund:
After receiving an overwhelming number of inquiries from citizens and companies who want to help, Houston Mayor Sylvester Turner and County Judge Ed Emmett have established the Hurricane Harvey Relief Fund that will accept tax deductible flood relief donations for victims that have been affected by the recent floods. The fund will be housed at the Greater Houston Community Foundation, a 501(c)(3) public charity.
About the Artists:
Dave Halston comes with an impressive resume – working a multitude of theatres, casinos, special events and private parties coast to coast – and in most cases, leaving the audience stunned. As one observer described it, “Dave Halston somehow casts a spell, and they always want more.” Even Barbara Sinatra was brought to tears when Dave performed for her at an exclusive private event. She called his performance “wonderful” and noted specifically the fine job Dave did with Sinatra’s signature song “My Way”.
In addition to Mrs. Sinatra, Dave has also entertained Jeanne Martin (Mrs. Dean Martin), recording artists Michael Feinstein, Steve Tyrell and Mr. Las Vegas himself, Wayne Newton, among other notables.
Suzanne Goulet was born in Montreal, Canada and has been dancing since the age of 3. She starred in “Fantastique” at the Sheraton Bal Harbour in Miami Beach, then at the Sands Casino in Atlantic City and at the Condado Plaza in San Juan, Puerto Rico. She then joined “Hooray for Hollywood” for an international tour to Spain, Switzerland and Japan. She also choreographed and danced for a show on the “Song of America” cruise ship from RCCL. After studying voice in New York City, she won the “Smirnoff Makes You A Star” competition and began her career as a tribute artist.
In 1996, Suzanne joined “Legends in Concert” at Bally’s Grand in Atlantic City. Then she followed the show to the Imperial Palace in Las Vegas where she received rave reviews and numerous awards.
Show Details:
“FRANK & LIZA”
A Musical Tribute to Frank Sinatra and Liza Minnelli
2:30PM | Sunday, September 24th, 2017
TICKETS: $25
The Mary C. O’Keefe Cultural Center of Arts and Education
1600 Government Street
Ocean Springs, Mississippi 39564
228.818.2878
The famous HIV virus discoverer Robert Gallo joined Medisun Medical Group
The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun
Bringing the best cancer and AIDS treatment technologies to China
Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun
In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.
Dr. Robert Charles Gallo
Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.
Mr. Terry L. Lierman, founder of the US FDA, joined Medisun
At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.
Mr.Terry L.Lierman
Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance
At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.
Mr. Danny Wong
Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.
Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.
The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.
MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER
Medisun Medical Laboratory (Hong Kong)
Medisun Medical Laboratory (Hong Kong)
Medisun announced that he will join the Biden Cancer Lunar Plan
At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.
The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.
The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.
GVN achieves its goals through three strategic action platforms:
Support research
Public education
Advocate a statement supporting the global virus network
Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.
Source: http://www.medisun.hk/
The famous american virologist Robert Gallo joined Medisun Medical Group
The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun
Bringing the best cancer and AIDS treatment technologies to China
Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun
In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.
Dr. Robert Charles Gallo
Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.
Mr. Terry L. Lierman, founder of the US FDA, joined Medisun
At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.
Mr.Terry L.Lierman
Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance
At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.
Mr. Danny Wong
Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.
Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.
The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.
MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER
Medisun Medical Laboratory (Hong Kong)
Medisun Medical Laboratory (Hong Kong)
Medisun announced that he will join the Biden Cancer Lunar Plan
At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.
The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.
The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.
GVN achieves its goals through three strategic action platforms:
Support research
Public education
Advocate a statement supporting the global virus network
Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.
Source: http://www.medisun.hk/